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Appendix 1. Simulation study
In order to increase the Sarcome-13/OS2016 study's power to reliably detect smaller, but more plausible, effects, we seek to augment trial data with relevant historical information. To incorporate historical information on control arm derived from individual patient data of Sarcome-09/OS2006 trial, we used a power prior using to control the impact of the historical data on the posterior distribution, where means that we do not incorporate any historical data, and means that we give equal weight to historical and new data. To incorporate historical aggregate information about the treatment effect, defined as the log-Hazard Ratio (log-HR), we used a mixture prior with reflecting the prior plausibility of the commensurability of the historical treatment effect estimate and the treatment effect in the Sarcome-13/OS2016 trial; means that we do not incorporate any historical data, and means that we give equal weight to historical and new data. For a formal definition of the prior distribution, see Brard et al. [submitted] .
The trial operating characteristics of this approach combining historical aggregate treatment effect and individual historical controls in the data analysis of the new trial and the calibration of and , have been studied in a previous extensive simulation study [Brard et al, submitted] . In this simulation study, a piecewise exponential modelling with three pieces was used to model EFS distribution of the new trial and estimate mifamurtide relative treatment effect with partition times set at [0,1), [1, 2) and [2,+∞) years based on individual historical control data (N = 165). So, we generated survival data with a sample size of 105 patients in the new trial. Following this work, it appears that and were a good trade-off between gain in power and increased bias and type-I error.
Small changes occurred in the final version of the Sarcome-13/OS2016 protocol compared to the draft used in the previous simulation study, in terms of eligibility criteria for the current trial leading to i) a different set of historical Sarcome-09/OS2006 patients (from 165 patients and 73 events to 256 patients and 116 events) and ii) a larger sample size of the planned Sarcome-13/OS2016 trial (105 initially to 126 patients in the submitted version). Partition times of the piecewise exponential distribution were also refined from 1 and 2 years to 0.3 and 1.6 years.
2 Consequently, we decided to re-run a new simulation study with a small set of scenarios (See Table A1 ) to explore the neighbourhood of the parameters set previously defined We considered the following pairs of weights:
In scenarios S1-S4, we set simulation model parameters equal to the estimates obtained from fitting a piecewise exponential model, to the subset scenario; S1, S5, S9), (ii) a treatment effect inferior to the historical treatment effect derived from the overall treatment effect based on INT 0133 estimates, i.e.
('disappointing effect' scenario; S2, S6, S10), (iii) a treatment effect equal to the estimated historical treatment effect, i.e.
('historical effect' scenario; S3, S7, S11), and (iv) a treatment effect equal to the target effect of the Sarcome-13/OS2016 trial which is superior to the historical treatment effect, i.e.
('anticipated effect' scenario; S4, S8, S12).
For each of the 12 scenarios, 5 000 trials were simulated with fixed sample size n = 126, and a uniform censoring rate of 5%.
3 Bayesian survival models were fitted using Markov chain Monte Carlo. We ran one chain, sampling using a Metropolis-Hastings algorithm for 20 000 iterations with a 'burn-in' period of 5 000 iterations, leaving 15 000 samples for posterior inferences.
Convergence to the stationary distribution was assessed by Geweke's diagnostic test. We stipulated Normal(0, 10 000) prior distributions for , , and (log scale), and Normal(0, 10) for the vague component of the mixture prior. If the posterior probability that the regression coefficient of the treatment effect was less than 0 (corresponding to a hazard ratio < 1) fell beyond 0.90, the objective was considered met and the trial ended in positive conclusion.
For each simulation scenario, we estimated the bias of the posterior estimate of the treatment effect as the difference between the sample mean of the 5 000 posterior means of and the scenario-specific true treatment effect. Table A2 . Impact of and on the operating characteristics for scenarios S1 to S4 (commensurate control arm). Table A3 . Impact of and on the operating characteristics for scenarios S5 to S8 (negative prior-data conflict). Table A4 . Impact of and on the operating characteristics for scenarios S9 to S12 (positive prior-data conflict). 
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